Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Inovio Pharmaceuticals (INO), Pluristem (PSTI) and Mallinckrodt (MNK).
Inovio Pharmaceuticals (INO)
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Inovio Pharmaceuticals today and set a price target of $13. The company’s shares closed yesterday at $3.95.
Selvaraju observed:
“Our 12-month price target is derived from a market value of the firm at $1.3B, which includes a discounted cash flow based asset value of $1.4B for 15% discount rate, 2% terminal growth rate, 80% probability of success, excluding $78.5M debt and assuming 105M shares outstanding at the end of.”
According to TipRanks.com, Selvaraju is a 3-star analyst with an average return of 2.7% and a 39.2% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Inovio Pharmaceuticals with a $10.67 average price target.
See today’s analyst top recommended stocks >>
Pluristem (PSTI)
H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Pluristem today and set a price target of $3.50. The company’s shares closed yesterday at $0.68.
Ramakanth observed:
“We have updated our financial model to reflect the reported results. For FY2019, we expect the company to report revenues of $0.05M and a net loss of $0.31 per share. The company reported cash and cash equivalents of $11.2M at the end of the period and completed equity financing, raising net proceeds of $19.5M. Pluristem holds pro forma cash and cash equivalents of 30.7M, which we believe is sufficient to fund operations into CY2Q20.”
According to TipRanks.com, Ramakanth is ranked 0 out of 5 stars with an average return of -8.5% and a 33.9% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Gritstone Oncology Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Pluristem with a $3.25 average price target, implying a 380.2% upside from current levels. In a report issued on April 23, Maxim Group also maintained a Buy rating on the stock with a $3 price target.
Mallinckrodt (MNK)
In a report released today, Irina Rivkind Koffler from Mizuho Securities reiterated a Hold rating on Mallinckrodt, with a price target of $25. The company’s shares closed yesterday at $16.39.
Rivkind Koffler wrote:
“We reiterate our Neutral rating, as we remain concerned about longer term competitive risk for Mallinckrodt’s key brands, with minimal pipeline upside.”
According to TipRanks.com, Koffler is a 4-star analyst with an average return of 3.4% and a 41.7% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries Limited, Bausch Health Companies Inc, and Assertio Therapeutics Inc.
Mallinckrodt has an analyst consensus of Moderate Buy, with a price target consensus of $35.60.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
